I run the operations at Quintessence Biosciences, a clinical stage biopharmaceutical company focused on development of proprietary cancer therapies. We licensed technology from the UW Madison (WARF) and the company has advanced the EVade™ Ribonucleases (RNases), from discovery to clinical.
Our technology allows for the attack of the RNA inside cancer cells and the EVade™ RNases have shown broad efficacy in model systems, including tumor growth inhibition against breast, colon, non-small cell lung, pancreatic and prostate cancers. Our first drug, QBI- 139, is in a Phase 1 clinical trial at The University of Texas MD Anderson Cancer Center and The University of Wisconsin Carbone Cancer Center.
While a frog RNase has been in clinical trials (Onconase from Tamir Biotechnology), QBI-139 appears to be significantly differentiated by the therapeutic window seen in in vivo model systems and the clinic.
In addition to development work for the next stage of clinical trials, we are pursuing additional products from our EVade™ RNase technology. To date, we have raised approximately $17M from individual investors.
Our goal is to provide a positive new treatment option for patients while also ensuring a return for shareholders.